ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 Shares of Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 10,796 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $1.58, for a total value of $17,057.68. Following the completion of the transaction, the insider now directly owns 580,714 shares in the company, valued at approximately $917,528.12. This represents a 1.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ALX Oncology Stock Down 6.6 %

Shares of NASDAQ ALXO opened at $1.56 on Friday. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $82.28 million, a PE ratio of -0.52 and a beta of 1.04. The firm’s 50-day moving average is $1.52 and its 200-day moving average is $2.90. ALX Oncology Holdings Inc. has a 1 year low of $1.19 and a 1 year high of $17.83.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research report on Wednesday, December 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. Finally, Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $12.00 to $2.00 in a research report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and an average target price of $8.50.

Hedge Funds Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP lifted its stake in shares of ALX Oncology by 423.0% in the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after purchasing an additional 514,133 shares during the period. Privium Fund Management B.V. increased its holdings in ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after purchasing an additional 112,093 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in ALX Oncology by 87.2% during the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock worth $2,642,000 after buying an additional 204,100 shares during the last quarter. XTX Topco Ltd bought a new position in ALX Oncology during the third quarter worth about $578,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of ALX Oncology during the 2nd quarter worth about $1,834,000. 97.97% of the stock is owned by institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.